Advances in Frontline Gastric, GEJ, and Esophageal Adenocarcinoma From ESMO 2025 - Episode 4
Where Domvanalimab/Zimberelimab/Chemo Could Fit in the Advanced Gastric/GEJ/Esophageal Adenocarcinoma Paradigm
Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss the potential clinical implications of the investigation of domvanalimab plus zimberelimab and FOLFOX in gastric/GEJ/esophageal adenocarcinoma.
Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, explore how positive STAR-221 results could transform first-line management for advanced gastric, GEJ, and esophageal adenocarcinoma. They examine how the domvanalimab plus zimberelimab and FOLFOX regimen might fit within the current therapeutic landscape and potentially broaden available immunotherapy options. Janjigian and Wainberg consider whether this approach could emerge as a new standard of care and what factors would influence real-world adoption.
Related Content:
